SEC Form 3 FORM 3

UNITED STATES SECURITIES AND EXCHANGE

COMMISSION

Washington, D.C. 20549

3235-OMB Number: 0104

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person [*] MCCOY JOHN A. JR.			2. Date of Requiring (Month/Da 09/01/20	Statement y/Year)	3. Issuer Name and Ticker or Trading Symbol <u>ABBOTT LABORATORIES</u> [ABT]						
(Last) 100 ABBO	(First) (Mide ITT PARK ROAD	dle)			4. Relationship of Reporting Issuer (Check all applicable) Director	Person(s) to 10% Owner		5. If Amendment, Date of Original Filed (Month/Day/Year)			
(Street) ABBOTT PARK (City)	IL 600 (State) (Zip)				X Officer (give title below) VICE PRESI	Other (specify below) DENT		6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person			
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Security (Instr. 4)					2. Amount of Securities Beneficially Owned (Instr. 4)	3. Owne Form: D (D) or In (I) (Instr	Direct Owne ndirect		ture of Indire ership (Instr. !		
Common shares without par value					15,215	E)				
Common shares without par value					55 ⁽¹⁾	I	I Prof		fit Sharing Trust		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
E			2. Date Exercisable and Expiration Date Month/Day/Year)		3. Title and Amount of Se Underlying Derivative Sec (Instr. 4)		urity Conver or Exer		5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr.	
			ate xercisable	Expiration Date	Title	Amount or Number of Shares	Price of Derivative Security		Direct (D) or Indirect (I) (Instr. 5)	5)	
Option (righ	t to buy) ⁽²⁾	()2/19/2022	02/18/2031	Common Shares	13,369	124.	04	D		
Option (righ	t to buy) ⁽³⁾	()2/18/2023	02/17/2032	Common Shares	16,632	117.	58	D		
Option (righ	t to buy) ⁽⁴⁾	()2/17/2024	02/16/2033	Common Shares	12,759	106.	24	D		

Explanation of Responses:

1. Balance in the Abbott Laboratories Stock Retirement Trust as of September 1, 2023.

2. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,456 on February 19, 2022, 4,456 on February 19, 2023, and 4,457 on February 19, 2024.

3. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 5,544 on February 18, 2023, 5,544 on February 18, 2024 and 5,544 on February 18, 2025.

4. Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 4,253 on February 17, 2024, 4,253 on February 17, 2025, and 4,253 on February 17, 2026.

<u>/s/ John A. McCoy, Jr. by</u> Jessica H. Paik, Attorney-	<u>09</u>
<u>in-Fact</u>	
** Signature of Reporting Person	Da

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

9/06/2023

ate

OMB APPROVAL

POWER OF ATTORNEY

The undersigned constitutes and appoints HUBERT L. ALLEN, JESSICA H. PAIK, and AARON N. RICE, and each of them individually, as the undersigned's true and lawful attorney-in-fact and agent, with full power of substitution and re-substitution, for the undersigned and in the undersigned's name, place and stead, to prepare, sign, and file with the Securities and Exchange Commission ("SEC") any and all forms and documents required under federal securities laws, including Rule 144 of the Securities Act of 1933, as amended, and Section 16(a) of the Securities Exchange Act of 1934, as amended, a Form ID and any other documents necessary to obtain codes, passphrases and passwords necessary to make electronic filings, and any other documents in connection therewith, granting unto said attorney-in-fact and agent full power and authority to do and perform each act and thing requisite, necessary or desirable to be done under said Rule 144 and Section 16(a), as fully for all intents and purposes as the undersigned might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent may lawfully do or cause to be done by virtue hereof.

A copy of this power of attorney shall be filed with the SEC. The authorization set forth above shall continue in full force and effect until the undersigned is no longer required to make filings under Rule 144 and Section 16(a) or if earlier, until the undersigned revokes such authorization by written instructions to the attorney-in-fact.

Date: July 24, 2023

/s/ John A. McCoy, Jr. Signature of Reporting Person

John A. McCoy, Jr. Abbott Laboratories 100 Abbott Park Road Abbott Park, IL 60064